Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Cited by (1,433)

Items 1,101–1,200 of 1,433

1. The role of immunotherapy in eliminating high-risk treatments for pediatric cancer
   Zahra Farhoud, Sepehr Bozorgchenani · 2021 · Journal of Current Biomedical Reports
2. Treatment of multiple myeloma in 2021
   Jiří Minařík · 2021 · Klinická farmakologie a farmacie
3. Post-protocol therapy and informative censoring in the CANDOR study
   Tomer Meirson, Gal Markel, Vinay K. Prasad · 2022 · The Lancet Oncology
4. Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
   Waqqas Tai, Ahsan Wahab, Diana Franco, Zunairah Shah, Aqsa Ashraf, Qurrat‐ul‐ain Abid, Yaqub Nadeem Mohammed, Darshan Lal, Faiz Anwer · 2022 · Antibodies
5. Cost-effectiveness: maximizing impact by meticulous data
   Hedwig M. Blommestein, Sonja Zweegman · 2022 · Blood
6. Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma
   Massimo Offidani, Laura Corvatta, Sara Bringhen, Silvia Gentili, Rossella Troia, Laura Maracci, Alessandra Larocca, Francesca Gay, Pietro Leoni, Mario Boccadoro · 2016 · European Journal Of Haematology
7. Clinical trials evaluating potential therapies for light chain (AL) amyloidosis
   Eli Muchtar, Morie Abraham Gertz · 2017 · Expert Opinion on Orphan Drugs
8. Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers
   Muhammad Shaalan Beg, Jeffrey John Meyer · 2018 · Journal of Gastrointestinal Oncology
9. Znaczenie minimalnej choroby resztkowej w szpiczaku plazmocytowym — Stanowisko Polskiego Konsorcjum Szpiczakowego
   Krzysztof Jamroziak, Agnieszka Krzywdzińska, Iwona Solarska · 2018 · Hematologia
10. Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?
    Hira S. Mian, Tanya Marya Wildes · 2018 · Drugs & Aging
11. International Forum on typing and matching strategies in patients on anti‐ CD 38 monoclonal therapy
    Karen M. K. de Vooght, Miquel Lozano, J‐L. Bueno et al. · 2018 · Vox Sanguinis
12. The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis
    Gan-Lin He, Duorong Xu, Waiyi Zou, Sui-Zhi He, Juan Li · 2018 · BioMed Research International
13. The therapeutic role of natural killer cells in multiple myeloma
    Ghulam Rehman Mohyuddin, Muzaffar H. Qazilbash · 2019 · Advances in Cell and Gene Therapy
14. Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?
    Hyunkyung Park, Ja Min Byun, Sung‐Soo Yoon · 2020 · Journal of Clinical Medicine
15. Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
    Seok Jin Kim, Danbee Kang, Yong Park, Yeung‐Chul Mun, Kihyun Kım, Jin Seok Kim, Chang‐Ki Min, Juhee Cho · 2021 · Supportive Care in Cancer
16. Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
    Torben Plesner · 2021 · Journal of Clinical Medicine
17. Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers
    Gergely Varga, András Dávid Tóth, Virág Réka Szita, Zoltán Csukly, Apor Hardi, Júlia Weisinger, Zsolt Nagy, Elvira Altai, Annamária Rencsik, Márk Plander et al. · 2021 · Pathology & Oncology Research
18. Black Disparities in Targeted Therapy Clinical Trials – A Call for Future Reset
    Shobi Venkatachalam, Mohammed Al‐Jumayli · 2021 · The Journal of Healthcare Ethics & Administration
19. Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients
    Paola Tacchetti, Serena Rocchi, Simona Barbato, Elena Zamagni, Lucia Pantani, Katia Mancuso, Ilaria Rizzello, Michèle Cavo · 2021 · Expert Review of Hematology
20. Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics
    Rafael Alonso, Juan José Lahuerta · 2022 · Frontiers in Oncology
21. Minimal Residual Disease in Multiple Myeloma—Current Approaches and Future Clinical Implications
    Theresia Akhlaghi, Ross Firestone, Malin L. Hultcrantz · 2022 · Hemato
22. CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment
    Dawn Swan, Robert B. Henderson, Cian McEllistrim, Serika D. Naicker, John Quinn, Mary R. Cahill, Vitaliy Mykytiv, Elizabeth Lenihan, Emer Mulvaney, Marc Nolan et al. · 2022 · Clinical Lymphoma Myeloma & Leukemia
23. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia
    Karima Amaador, Marie José Kersten, Monique C. Minnema, Josephine M. I. Vos · 2022 · Leukemia & lymphoma/Leukemia and lymphoma
24. Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies
    Mihaela Andreescu · 2024 · Cureus
25. Multiples Myelom
    Marc‐Andrea Baertsch, Hartmut Goldschmidt · 2017 · Der Internist
26. A look at treatment strategies for relapsed multiple myeloma
    Giusy Cetani, Mario Boccadoro, Stefania Oliva · 2018 · Expert Review of Anticancer Therapy
27. Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?
    Susanna Gassiot, Yolanda González, Mireia Morgades, Cristina Motlló, Victòria Clapés, Clara Maluquer, Gladys Ibarra, Laura Abril, Josep‐María Ribera, Albert Oriol · 2019 · Clinical Lymphoma Myeloma & Leukemia
28. Monoclonal antibody utilization characteristics in patients with multiple myeloma
    Sikander Ailawadhi, Taimur Sher, Abdel‐Ghani Azzouqa, Zahara Meghji, Tania Jain, Prachi Jani, Salman Ahmed, Nancy N. Diehl, Vivek Roy, Vishal S. Shah et al. · 2019 · Anti-Cancer Drugs
29. Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma
    Louis S. Williams, Beatrix Razzo, Jessica Caro, Gareth John Morgan · 2019 · touchREVIEWS in Oncology & Haematology
30. Changes in primary outcome and sample size measures after initiation of accrual among trials supporting approval of drugs for hematological malignancies by the US food and drug administration
    Irina Amitai, Pia Raanani, Daniel Shepshelovich · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
31. Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population
    Hannah Marie Cherniawsky, Hatem Mahmoud Alahwal, Yasser Abou Mourad et al. · 2021 · Clinical Lymphoma Myeloma & Leukemia
32. Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
    Christie P.M. Verkleij, Wassilis S.C. Bruins, Sonja Zweegman, Niels W.C.J. van de Donk · 2021 · Hemato
33. Daratumumab
    Vishnu Gopal, Biswajit Dubashi · 2020 · Indian Journal of Medical and Paediatric Oncology
34. Dual chimeric antigen receptor T cells targeting CD38 and SLAMF7 with independent signalling demonstrate efficacy and safety in preclinical models of Multiple Myeloma
    Nathalie Roders, Cécilia Nakid-Cordero, Fabio Raineri, Maxime Fayon, Audrey Abecassis, Caroline Choisy, Elisabeth Nelson, Claire Maillard, David GARRICK, Alexis Talbot et al. · 2023 · Research Square
35. CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma
    Benjamin T. Diamond, Linda Banovic Baughn, Mansour Poorebrahim, Alexandra Maria Poos, Holly Lee, Marcella Kaddoura, Julia Erin Wiedmeier, Michael A. Durante, Gregory E. Otteson, Dragan Jevremović et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
36. Case Report of an Unusual Tumor in an Adult With a TP53 Germline Mutation
    Julie Castiaux, Isabelle Vandernoot, Julie Dallemagne, Marie Bruneau, Mélanie Delaunoy, Xavier Peyrassol, Pierre Heimann, Virginie De Wilde, Alice Wolfromm · 2020 · Clinical Lymphoma Myeloma & Leukemia
37. Original Versus Generic Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Comparison of Effectivity and Adverse Events
    Ali Zahit Bolaman, Atakan Turgutkaya, Birsen Sahip, Cem Selim, Hilal Eroğlu Küçükerdiler, Şehmus Ertop, Gökhan Sargın, İrfan Yavaşoğlu · 2021 · Turkish Journal of Hematology
38. At what point are we on the way to optimally treat multiple myeloma patients over 75 years of age in 2023?
    Agata Tyczyńska, Jan Maciej Zaucha · 2023 · Advances in Clinical and Experimental Medicine
39. Nonviral cryoglobulinemic vasculitis: an updated review for clinical practice
    Andrea Núñez-Conde, Ignasi Rodríguez‐Pintó, David A. Alba-Garibay · 2023 · Vessel Plus
40. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands
    Andrea Díaz-Tejedor, Javier Rodríguez‐Ubreva, Laura Ciudad et al. · 2024 · International Journal of Molecular Sciences
41. Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials
    Sara A. Almansour, Mohammad A. Y. Alqudah, Ziad Abuhelwa et al. · 2024 · Therapeutic Advances in Medical Oncology
42. Cryptococcal Pneumonia in Multiple Myeloma: A Case Report
    Dustin Epstein, Joanna Herrera, Tiffany Nong · 2024 · Cureus
43. Real-World Effectiveness and Safety of Intravenous Daratumumab in Patients with Multiple Myeloma: A Multicenter, Observational Study from Korea
    Youngil Koh, Sung‐Soo Yoon, Kihyun Kım, Je‐Jung Lee, Sung‐Hoon Jung, Sang Eun Yoon, Sung‐Soo Park, Y.S. Park, Soomin Yoon, Chang‐Ki Min · 2024 · Cancer Research and Treatment
44. A Markov model for estimating the cost-effectiveness of immunotherapy for newly diagnosed multiple myeloma patients
    Massimo Bilancia, Antonio Giovanni Solimando, Fabio Manca, Angelo Vacca, Roberto Ria · 2025 · Computational Statistics & Data Analysis
45. Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies
    Federico Caroni, Vincenzo Sammartano, Paola Pacelli, Anna Sicuranza, Margherita Malchiodi, Andreea Dragomir, Sara Ciofini, Donatella Raspadori, Monica Bocchia, Alessandro Gozzetti · 2025 · Pharmaceuticals
46. Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis
    Arleigh B. Robertson McCurdy, Engin Gul, Donna Ellen Reece, Michael Patvin Chu, Victor Hugo Jimenez-Zepeda, Martha Louzada, Kevin Song, Hira S. Mian, Michaël Sébag, Darrell J. White et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
47. Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
    Walter Martin Gregory, Thomas J. Prior, J. Blake Bartlett, Pieter Sonneveld, Meletios Athanasios Dimopoulos, Philippe Moreau, Saad Z. Usmani, Thierry T.F. Facon · 2025 · Clinical Cancer Research
48. Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data
    Ning Lyu, Zahra Majd, Bilqees Fatima, Zhen Zeng, Hua Chen, Susan Abughosh · 2025 · Cancer Treatment and Research Communications
49. Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined
    Ruben Van Dijck, Zoran Erjavec, John‐John B. Schnog · 2025 · American Journal of Hematology
50. A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
    Chandramouli Nagarajan, Wei‐Ying Jen, Melissa Gaik Ming Ooi, Sanjay De Mel, Cinnie Yentia Soekojo, Soo‐Young Yoon, Melinda Si Yun Tan, Yunxin Chen, Xinhua Li, Yogesh Mahadev Pokharkar et al. · 2025 · Blood Cancer Journal
51. Overcome Daratumumab’ severe reaction with desensitization in relapsed multiple myeloma
    Trang L. Nguyen, Truc Phan, Mai Vu, K. Huynh, Yi Hyeon Gyu, Tuan Duc Nguyen, Loi Phan, Tuan Duc Nguyen, Dinh Van Nguyen · 2025 · Journal of Oncology Pharmacy Practice
52. Treatment Patterns of Patients With Multiple Myeloma in a Real-World Setting in Spain. How are Triple-Class Exposed Patients Being Managed?
    Julia Llinares, Sofía Toribio-Castelló, Luis Fernando García, Tamara Iglesias, Ana Heredero, Pablo Rebollo, I. Ricote, María‐Victoria Mateos · 2025 · Clinical Lymphoma Myeloma & Leukemia
53. Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline
    Matthew W. Jenner, Kevin D. Boyd, Satarupa Choudhuri, Christopher Parrish, Mamta Krishnan Garg, Simon Stern, the British Society of Haematology and UK Myeloma Society · 2025 · British Journal of Haematology
54. Evaluation of the performance of new daratumumab-specific immunofixation electrophoresis reflex agent and the timing of M-protein measurement
    Naomi Yasuda, Masako Nishikawa, Naoyuki Yoshikawa · 2025 · Journal of the Japan Society of the Reticuloendothelial System
55. Daratumumab in severe Evans syndrome: a case report
    Stefan M. Hillmann, Hendrik Brockhoff, Sarah Loebel · 2026 · Frontiers in Hematology
56. Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations
    Annamaria Gullà, Madhav V. Dhodapkar, Hermann Einsele, Marc Steffen Raab, Antonio Giovanni Solimando, Cirino Botta, Marcello Turi, Lilli Sophie Sester, Andrew Jay Portuguese, Torsten Steinbrunn et al. · 2026 · Blood Cancer Discovery
57. Time and Resource Implications of Subcutaneous Daratumumab-Based versus Intravenous Isatuximab-Based Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
    Emma Smith, Alessandro Camera, Alex Bird · 2026 · Oncology and Therapy
58. Precision targeting of CD38 in immune thrombocytopenia: Mechanistic foundations and therapeutic implications
    Xin Zhou, Yubao Liu, Peipei Zhang, Ningning Shan · 2026 · European Journal of Pharmacology
59. Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens
    Emiliano Barbieri, Laura Arletti, Micol Quaresima et al. · 2026 · European Journal Of Haematology
60. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma
    Marco Salvini, Francesca Bonello, Mario Boccadoro, Alessandra Larocca · 2016 · Expert Review of Anticancer Therapy
61. Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma
    Branka Petričević, Wolfgang Hilbe, Niklas Zojer · 2017 · memo - Magazine of European Medical Oncology
62. New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review
    Ol’ga Mikhailovna Votyakova · 2017 · Clinical oncohematology
63. Treatment of Patients in First or Second Relapse
    Andrew Jenho Yee, Noopur S Raje · 2017 · Springer eBooks
64. DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA
    Рыжко Вячеслав Владимирович, М. Л. Канаева · 2017 · Meditsinskiy sovet = Medical Council
65. Custo-efetividade do esquema com daratumumabe, bortezomibe e dexametasona em comparação com terapias à base de carfilzomibe, elotuzumabe e ixazomibe para o tratamento de mieloma múltiplo recidivado e refratário na perspectiva de um pagador do sistem
    Cyntia Fioratti, Ricardo Rosim, Luciana Scaccabarozzi · 2018 · Jornal Brasileiro de Economia da Saúde
66. Utilisation du daratumumab dans le myélome multiple
    Carolyne Croizier, Sébastien Bailly · 2018 · Bulletin du Cancer
67. Optimising Treatment in Relapsed, Refractory Multiple Myeloma
    Monique C. Minnema, Maria Gavriatopoulou · 2018 · European Oncology & Haematology
68. Guérison du myélome multiple : un objectif envisageable à court terme ?
    Thierry T.F. Facon · 2018 · Bulletin de l Académie Nationale de Médecine
69. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant
    Peter H. Langer, Ina Monsef, Christof Scheid · 2020 · Cochrane Database of Systematic Reviews
70. [Advances in the diagnosis and treatment of multiple myeloma].
    Beihui Huang, J Li · 2018 · PubMed
71. Treatment With Elotuzumab in Combination With Dexamethasone Achieves a Complete Remission in a Previously Treated Patient With Multiple Myeloma: A Case Report
    Sydney Meyers, Chace Henning, Regina A. Swift, Benjamin Eades, Tanya Magazinnik Spektor, James R. Berenson · 2020 · Clinical Lymphoma Myeloma & Leukemia
72. Approaching the first relapse after autologous transplant in multiple myeloma
    Shebli Atrash, Issam S. Hamadeh, Ashley Matusz‐Fisher, Ami P Ndiaye, Manisha Bhutani, Peter Michael Voorhees, Barry Paul, Saad Z. Usmani · 2020 · Advances in Cell and Gene Therapy
73. Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma
    Hirohiko Shibayama, Morio Matsumoto, Hiroshi Kosugi, Kazuhiro Shibayama, Hiroshi Yamazaki, Shinsuke Iida · 2020 · International Journal of Hematology
74. Análise de custo por desfecho das novas terapias de combinação tripla com lenalidomida para o mieloma múltiplo recidivado/refratário no Brasil
    Straus Tanaka, Rana Maroun, Carolina Martinez · 2020 · Jornal Brasileiro de Economia da Saúde
75. The Modern Age of Monoclonal Antibodies: The Revolution of Daratumumab
    Gianfranco Lapietra, Francesca Fazio, Maria Teresa Petrucci · 2021 · IntechOpen eBooks
76. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma
    Anna Piggin, Henry Miles Prince · 2021 · Expert Review of Hematology
77. Strategies to Overcome High-Risk Multiple Myeloma
    Larysa Jessica Sanchez · 2021 · The Cancer Journal
78. The evolving role and utility of off-label drug use in multiple myeloma
    James Hart Stoeckle, Faith E. Davies, Louis S. Williams, Eileen Mary Boyle, Gareth John Morgan · 2021 · Exploration of Targeted Anti-tumor Therapy
79. Experience of Daratumumab in Six Patients With Multiple Myeloma and Kidney Failure
    Atakan Turgutkaya, Ali Zahit Bolaman, İrfan Yavaşoğlu · 2021 · Plasmatology
80. Onkologika
    Wolf-Dieter Ludwig, Arnold Ganser, Georg Maschmeyer · 2021 · Springer eBooks
81. Transfusion Practices in the Era of Anti-CD38 Antibodies in the Treatment of Multiple Myeloma: A Mini Review
    2017
82. Challenges and Opportunities to Access Innovation in Latin America: The Case of Combination Therapies for Multiple Myeloma
    Cristina Gutierrez Delgado, Virginia Abello, Martha Alvarado, Daniel Lew, Darı́o Londoño, Elizabeth McElwee, Mariana Rico-Restrepo, Natalia Paola Schutz, Stephen Doral Stefani, Ângelo Maiolino · 2022 · RAS Oncology & Therapy
83. To transplant or not to transplant in multiple myeloma
    Richard LeBlanc · 2022 · Canadian Hematology Today
84. Effectiveness of D-Rd program in the first line therapy of a 75-year-old female patient with multiple myeloma with high-risk cytogenetics. Clinical observation
    Yu. E. Ryabukhina, F. M. Abbasbeyli, Pervin A. Zeynalova, О. Л. Тимофеева, Купрышина Наталья Александровна, А. Г. Жуков · 2022 · MD-Onco
85. Multiple Myeloma
    Rami R. Kotb, Caroline Hart, Hadi Alphonse Goubran · 2022 · Springer eBooks
86. Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
    Zoé Van de Wyngaert, Florent Malard, Cyrille Hulin et al. · 2023 · Clinical Hematology International
87. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single‐centre retrospective study
    Alex Yang Ge, Chiung‐Yu Huang, Rahul Kumar Banerjee et al. · 2023 · British Journal of Haematology
88. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
    Muhamad Alhaj Moustafa, Ricardo Daniel Parrondo, Mays F Abdulazeez, Vivek Roy, Taimur Sher, Victoria R. Alegria, Rahma M. Warsame, Rafaël Fonseca, Ahsan Rasheed, Wilson I. Gonsalves et al. · 2023 · Anti-Cancer Drugs
89. Adoptive Immunotherapy and High-Risk Myeloma
    Catherine Duane, Michael E O'Dwyer, Siobhan V. Glavey · 2023 · Cancers
90. A synchronous therapy with daratumumab and enzymatic replacement therapy (ERT) in a patient with Gaucher disease and multiple myeloma
    Angela Rago, G. Palumbo, A. Tordi · 2023 · Annals of Hematology
91. IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
    Kazuhito Suzuki, Shingo Yano · 2023 · Life
92. Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
    Yu. E. Ryabukhina, Pervin A. Zeynalova, F. M. Abbasbeyli, О. Л. Тимофеева, Timur Teimurazovich Valiev, Купрышина Наталья Александровна, А. Г. Жуков · 2023 · Oncohematology
93. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
    Charalampos M. Charalampous, Utkarsh Goel, Prashant Kapoor et al. · 2023 · Blood Cancer Journal
94. Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma
    Moeen Mohammadi-Oroujeh, Ansa Mehreen, David L. Grinblatt · 2023 · Case Reports in Hematology
95. Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study
    Slavisa Ninkovic, Simon James Harrison, Je‐Jung Lee et al. · 2024 · Haematologica
96. Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone
    Karthik Ramasamy, Nizar Jacques Bahlis, Shaji Kunnathu Kumar, Arun Kumar, Holly Cranmer, Bingxia Wang, Jonathan Dabora, Richard Labotka, Paul Gerard Guy Richardson, Philippe Moreau · 2024 · Haematologica
97. Restoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature
    Noa Biran, David H. Vesole, Harsh Vallabh Parmar, Pooja M. Phull, Susan Kumka, Kimberley Doucette, Joshua Zenreich, Bianca DeAgresta, Alexandra Della Pia, Lisa Biamonte et al. · 2024 · Current Problems in Cancer Case Reports
98. Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
    Davor Galušić, Ivan Krečak, Viktor Blaslov, Krstulović Opara Anđela, Toni Valković, Sandra Bašić‐Kinda · 2025 · Biomedicines
99. Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study)
    Annemarie Glöckner, Stefan Olaf Schönland, Hermann Einsele · 2025 · BMC Cancer
100. The past, the present and the future of immune checkpoints inhibitors in multiple myeloma
     Valeria Tomarchio, Anna Crescenzi, Mariantonietta Tafuri, Martina Verri, Monica Di Cecca, Luigi Rigacci, Ombretta Annibali · 2025 · Expert Review of Hematology